Document is current
Any future updates will be listed below
-
Authors
Milhem, Mohammed M
Wise-Draper, Trisha M
Chandra, Sunandana
Hanna, Glenn J
Laux, Douglas E
Medina, Theresa M
Ansstas, George
Daud, Adil
Kelly, Ciara M
O’Day, Steven J
Perez, Cesar A
Wong, Michael K
Friedlander, Philip A
Kristedja, Timothy S
Burgess, Melissa A
Cowey, C Lance
Hanks, Brent A https://orcid.org/0000-0002-2803-3272
Weight, Ryan M
Daniel, Weston L https://orcid.org/0000-0003-2235-5630
Feltner, Douglas E
Mix, Scott
Sindelar, Laurel
Bexon, Alice S
Bexon, Martin F
Michel, Robert E
Bhatia, Shailender https://orcid.org/0000-0002-3816-2238
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03684785 at ClinicalTrials.govnct03684785 at ClinicalTrials.govDocuments that mention this clinical trial
423 Safety and preliminary efficacy of intratumoral cavrotolimod (AST-008), a spherical nucleic acid TLR9 agonist, in combination with pembrolizumab in patients with advanced solid tumors
https://doi.org/10.1136/jitc-2020-sitc2020.0423
Phase 1b/2 study evaluating safety, efficacy and immune effects of TLR9 agonist cavrotolimod with anti-PD-1 antibodies among patients with advanced solid tumors
https://doi.org/10.1136/jitc-2025-011651
nct03086278 at ClinicalTrials.govDocuments that mention this clinical trial
423 Safety and preliminary efficacy of intratumoral cavrotolimod (AST-008), a spherical nucleic acid TLR9 agonist, in combination with pembrolizumab in patients with advanced solid tumors
https://doi.org/10.1136/jitc-2020-sitc2020.0423
Phase 1b/2 study evaluating safety, efficacy and immune effects of TLR9 agonist cavrotolimod with anti-PD-1 antibodies among patients with advanced solid tumors
https://doi.org/10.1136/jitc-2025-011651
nct03684785 at ClinicalTrials.govDocuments that mention this clinical trial
Phase 1b/2 study evaluating safety, efficacy and immune effects of TLR9 agonist cavrotolimod with anti-PD-1 antibodies among patients with advanced solid tumors
https://doi.org/10.1136/jitc-2025-011651
Documents that mention this clinical trial
423 Safety and preliminary efficacy of intratumoral cavrotolimod (AST-008), a spherical nucleic acid TLR9 agonist, in combination with pembrolizumab in patients with advanced solid tumors
https://doi.org/10.1136/jitc-2020-sitc2020.0423
Phase 1b/2 study evaluating safety, efficacy and immune effects of TLR9 agonist cavrotolimod with anti-PD-1 antibodies among patients with advanced solid tumors
https://doi.org/10.1136/jitc-2025-011651
-
Funding
Funding for this research was provided by:
Exicure Inc (N/A)
- License Information
